CenExel Supports Metsera, Inc. in Successful Phase II Trial of MET-097 for Obesity and Metabolic Diseases
SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 /CenExel is pleased to announce its partnership with Metsera, Inc.
CenExel Research: CenExel Supports Metsera, Inc. in Successful Phase II Trial of MET-097 for Obesity and Metabolic Diseases
SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatm ...
BioSpace15h
Kallyope Discreetly Drops Disappointing Data for Oral Obesity Candidate
While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Low Price Pharma Stock to Invest In Right Now?
We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc.
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025Oral small ...